APA

Chase D. M., Sill M. W., Monk B. J., Chambers M. D., Darcy K. M., Han E. S., Buening B. J., Sorosky J. I., Fruehauf J. P. & Burger R. A. (20121016). Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. : Gynecologic oncology.

Chicago

Chase Dana M, Sill Michael W, Monk Bradley J, Chambers Mark D, Darcy Kathleen M, Han Ernest S, Buening Barbara J, Sorosky Joel I, Fruehauf John P and Burger Robert A. 20121016. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. : Gynecologic oncology.

Harvard

Chase D. M., Sill M. W., Monk B. J., Chambers M. D., Darcy K. M., Han E. S., Buening B. J., Sorosky J. I., Fruehauf J. P. and Burger R. A. (20121016). Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. : Gynecologic oncology.

MLA

Chase Dana M, Sill Michael W, Monk Bradley J, Chambers Mark D, Darcy Kathleen M, Han Ernest S, Buening Barbara J, Sorosky Joel I, Fruehauf John P and Burger Robert A. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. : Gynecologic oncology. 20121016.